3 recruiting, 2 not yet recruiting, 1 enrolling by invitation, 1 unknown. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 3, Not yet recruiting 2, Enrolling by invitation 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
Follow cGVHD: new trials by email Literature Review of cGVHD trials Research Report on cGVHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD) Belumosudil, Ruxolitinib - cGVHD | Phase 2 | Not yet recruiting | Dennis Kim | 53 | 2026-11-01 | 2026-10-02 |
| Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). Gecacitinib - cGVHD, HSCT | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 33 | 2026-03-16 | 2026-03-17 |
| BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation BPC-2001 - Graft -Versus-host-disease, aGVHD | Phase 2 | Recruiting | BioPhoenix Co., Ltd. | 50 | 2025-10-29 | 2026-08-17 |
| Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease Axatilimab, Extracorporeal Photopheresis - Chronic Graft Versus Host Disease, cGVHD | Phase 2 | Recruiting | University of Miami | 49 | 2025-05-05 | 2026-06-22 |
| Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD Iguratimod - cGVHD | Phase 1 / Phase 2 | Recruiting | Xuzhou Medical University | 20 | 2024-01-10 | 2026-09-30 |
| A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) ABSK021 - cGvHD | Phase 2 | Enrolling by invitation | Abbisko Therapeutics Co, Ltd | 64 | 2023-05-30 | 2024-08-12 |
| Belimumab for Treatment of cGVHD Following Allo-HCT Belimumab (Benlysta) - cGVHD | Phase 1 / Phase 2 | Withdrawn | xuna | 2022-01-01 | 2023-01-18 | |
| Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Rabbit ATG - aGVHD, cGVHD | Phase 2 | Unknown | Chinese PLA General Hospital | 60 | 2019-02-01 | 2022-02-22 |
Bronchiolitis Obliterans Syndrome (1) · Graft vs Host Disease (1)
Immune System Diseases (2) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1) · Graft vs Host Disease (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Organizing Pneumonia (1) · Respiratory Tract Diseases (1)
Antilymphocyte Serum (1) · KRN 7000 (1) · Photopheresis (1) · axatilimab (1) · belimumab (1) · belumosudil (1) · iguratimod (1) · ruxolitinib (1) · thymoglobulin (1)
Abbisko Therapeutics Co, Ltd (1) · BioPhoenix Co., Ltd. (1) · Chinese PLA General Hospital (1) · Dennis Kim (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · University of Miami (1) · Xuzhou Medical University (1) · xuna (1)
China (5) · Canada (1) · United States (1)
Daihong Liu, Doctor (1) · Trent P Wang, DO (1) · Xiaodong Mo, PhD (1)